Clinical trial NCT03755791: Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy
Official title: A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy
Study type: INTERVENTIONAL
Overall status: ACTIVE_NOT_RECRUITING
Phase: PHASE3
Conditions: Hepatocellular Carcinoma
Keywords: liver
cancer
hepatocellular
carcinoma
Lead sponsor: Exelixis
Sponsor class: INDUSTRY
First posted: 2018-11-28
Enrollment: 837
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: At least 740 eligible subjects with advanced HCC will be randomized in a 2:1:1 ratio. Experimental arm (at least 370 subjects) will receive cabozantinib plus atezolizumab. Control arm (at least 185 subjects) will receive sorafenib. Single-agent cabozantinib arm (at least185 subjects) will receive single-agent cabozantinib
Primary purpose: TREATMENT

Brief summary: This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

Detailed description: This is a multicenter, randomized, open-label, controlled Phase 3 trial of cabozantinib in combination with atezolizumab versus sorafenib in adults with advanced HCC who have not received previous systemic anticancer therapy in the advanced HCC setting. The primary objective of this study is to evaluate the effect of cabozantinib in combination with atezolizumab on the duration of progression-free survival (PFS) and duration of overall survival (OS) versus sorafenib. The secondary objective is to evaluate the activity of single-agent cabozantinib compared with sorafenib in this patient population.

Eligibility criteria: Inclusion Criteria:

* Histological or cytological diagnosis of HCC or clinical diagnosis of HCC in cirrhotic patients by CT or MRI per the AASLD 2018 or EASL 2018 guidelines.
* The subject has disease that is not amenable to a curative treatment approach (eg, transplant, surgery, ablation therapy) or locoregional therapy (eg, TACE).
* Measurable disease per RECIST 1.1 as determined by the Investigator.
* Barcelona Clinic Liver Cancer (BCLC) stage Category B or C.
* Child-Pugh Score of A.
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

Exclusion Criteria:

* Known fibrolamellar carcinoma, sarcomatoid HCC or mixed hepatocellular cholangiocarcinoma.
* Prior systemic anticancer therapy for advanced HCC including but not limited to chemotherapy, small molecule kinase inhibitors, and immune checkpoint inhibitors (ICIs). Subjects who have received local intratumoral or arterial chemotherapy are eligible; local anticancer therapy within ≥ 28 days before randomization
* Radiation therapy for bone metastasis within 2 weeks, any other radiation therapy within 8 weeks prior to randomization.
* Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 8 weeks prior to randomization.
* Concomitant anticoagulation with oral anticoagulants

Primary outcomes:
measure: Duration of Progression Free Survival (PFS) for the experimental arm vs. the control arm
timeFrame: Up to 27 months after the first subject is randomized. Defined as time from randomization to the earlier of progressive disease (PD) per RECIST 1.1 as determined by the Blinded Independent Radiology Committee (BIRC) or death from any cause.
measure: Duration of Overall Survival (OS) for the experimental arm vs. the control arm
timeFrame: Up to 36 months after the first subject is randomized. Defined as time from randomization to date of death from any cause.
Secondary outcomes:
measure: Duration of Progression Free Survival (PFS) for the single-agent arm vs. the control arm
timeFrame: Up to 20 months after the first subject is randomized.
Other outcomes:
Locations:
city: Phoenix
country: United States
facility: Exelixis Clinical Site #208
state: Arizona
city: Tucson
country: United States
facility: Exelixis Clinical Site #159
state: Arizona
city: La Jolla
country: United States
facility: Exelixis Clinical Site #44
state: California
city: Los Angeles
country: United States
facility: Exelixis Clinical Site #112
state: California
city: Orange
country: United States
facility: Exelixis Clinical Site #200
state: California
city: Rialto
country: United States
facility: Exelixis Clinical Site #2
state: California
city: San Diego
country: United States
facility: Exelixis Clinical Site #207
state: California
city: San Francisco
country: United States
facility: Exelixis Clinical Site #109
state: California
city: San Francisco
country: United States
facility: Exelixis Clinical Site #54
state: California
city: Washington
country: United States
facility: Exelixis Clinical Site #58
state: District of Columbia
city: Miami
country: United States
facility: Exelixis Clinical Site #191
state: Florida
city: Atlanta
country: United States
facility: Exelixis Clinical Site #4
state: Georgia
city: Chicago
country: United States
facility: Exelixis Clinical Site #195
state: Illinois
city: Chicago
country: United States
facility: Exelixis Clinical Site #120
state: Illinois
city: Baltimore
country: United States
facility: Exelixis Clinical Site #6
state: Maryland
city: Burlington
country: United States
facility: Exelixis Clinical Site #7
state: Massachusetts
city: Kansas City
country: United States
facility: Exelixis Clinical Site #11
state: Missouri
city: Kansas City
country: United States
facility: Exelixis Clinical Site #5
state: Missouri
city: Saint Louis
country: United States
facility: Exelixis Clinical Site #8
state: Missouri
city: Las Vegas
country: United States
facility: Exelixis Clinical Site #1
state: Nevada
city: New Brunswick
country: United States
facility: Exelixis Clinical Site #14
state: New Jersey
city: Albuquerque
country: United States
facility: Exelixis Clinical Site #76
state: New Mexico
city: Chapel Hill
country: United States
facility: Exelixis Clinical Site #12
state: North Carolina
city: Toledo
country: United States
facility: Exelixis Clinical Site #39
state: Ohio
city: Portland
country: United States
facility: Exelixis Clinical Site #176
state: Oregon
city: Philadelphia
country: United States
facility: Exelixis Clinical Site #88
state: Pennsylvania
city: Charleston
country: United States
facility: Exelixis Clinical Site #144
state: South Carolina
city: Dallas
country: United States
facility: Exelixis Clinical Site #199
state: Texas
city: Houston
country: United States
facility: Exelixis Clinical Site #154
state: Texas
city: Temple
country: United States
facility: Exelixis Clinical Site #19
state: Texas
city: Seattle
country: United States
facility: Exelixis Clinical Site #13
state: Washington
city: Seattle
country: United States
facility: Exelixis Clinical Site #46
state: Washington
city: Spokane
country: United States
facility: Exelixis Clinical Site #3
state: Washington
city: City of Buenos Aires
country: Argentina
facility: Exelixis Clinical Site #217
state: Buenos Aires
city: City of Buenos Aires
country: Argentina
facility: Exelixis Clinical Site #213
state: Buenos Aires
city: City of Buenos Aires
country: Argentina
facility: Exelixis Clinical Site #216
state: Buenos Aires
city: Pilar
country: Argentina
facility: Exelixis Clinical Site #219
state: Buenos Aires
city: Rosario
country: Argentina
facility: Exelixis Clinical Site #220
state: Santa Fe
city: Rosario
country: Argentina
facility: Exelixis Clinical Site #201
state: Santa Fe
city: Camperdown
country: Australia
facility: Exelixis Clinical Site #78
state: New South Wales
city: Darlinghurst
country: Australia
facility: Exelixis Clinical Site #165
state: New South Wales
city: Kingswood
country: Australia
facility: Exelixis Clinical Site #171
state: New South Wales
city: Kogarah
country: Australia
facility: Exelixis Clinical Site #126
state: New South Wales
city: Westmead
country: Australia
facility: Exelixis Clinical Site #155
state: New South Wales
city: Greenslopes
country: Australia
facility: Exelixis Clinical Site #142
state: Queensland
city: Kurralta Park
country: Australia
facility: Exelixis Clinical Site #17
state: South Australia
city: Box Hill
country: Australia
facility: Exelixis Clinical Site #107
state: Victoria
city: Heidelberg
country: Australia
facility: Exelixis Clinical Site #166
state: Victoria
city: Parkville
country: Australia
facility: Exelixis Clinical Site #72
state: Victoria
city: Nedlands
country: Australia
facility: Exelixis Clinical Site #190
state: Western Australia
city: Klagenfurt
country: Austria
facility: Exelixis Clinical Site #150
state: Kärnten
city: St. Pölten
country: Austria
facility: Exelixis Clinical Site #137
state: Lower Austria
city: Linz
country: Austria
facility: Exelixis Clinical Site #64
state: Oberosterreich
city: Graz
country: Austria
facility: Exelixis Clinical Site #198
state: Steiermark
city: Wien
country: Austria
facility: Exelixis Clinical Site #174
city: Brussels
country: Belgium
facility: Exelixis Clinical Site #50
state: California
city: Brussels
country: Belgium
facility: Exelixis Clinical Site #65
city: Edegem
country: Belgium
facility: Exelixis Clinical Site #169
city: Gent
country: Belgium
facility: Exelixis Clinical Site #148
city: Haine-Saint-Paul
country: Belgium
facility: Exelixis Clinical Site #57
city: Leuven
country: Belgium
facility: Exelixis Clinical Site #188
city: Liège
country: Belgium
facility: Exelixis Clinical Site #102
city: Salvador
country: Brazil
facility: Exelixis Clinical Site #184
state: BA
city: Belo Horizonte
country: Brazil
facility: Exelixis Clinical Site #89
state: MG
city: Belo Horizonte
country: Brazil
facility: Exelixis Clinical Site #98
state: MG
city: Curitiba
country: Brazil
facility: Exelixis Clinical Site #113
state: PR
city: Porto Alegre
country: Brazil
facility: Exelixis Clinical Site #203
state: RS
city: Barretos
country: Brazil
facility: Exelixis Clinical Site #175
state: SP
city: Jaú
country: Brazil
facility: Exelixis Clinical Site #121
state: SP
city: São Paulo
country: Brazil
facility: Exelixis Clinical Site #186
state: SP
city: São Paulo
country: Brazil
facility: Exelixis Clinical Site #156
state: SP
city: São Paulo
country: Brazil
facility: Exelixis Clinical Site #187
state: SP
city: São Paulo
country: Brazil
facility: Exelixis Clinical Site #181
state: SP
city: São Paulo
country: Brazil
facility: Exelixis Clinical Site #91
city: Calgary
country: Canada
facility: Exelixis Clinical Site #71
state: Alberta
city: Edmonton
country: Canada
facility: Exelixis Clinical Site #205
state: Alberta
city: Winnipeg
country: Canada
facility: Exelixis Clinical Site #34
state: Manitoba
city: Halifax
country: Canada
facility: Exelixis Clinical Site #222
state: Nova Scotia
city: Hamilton
country: Canada
facility: Exelixis Clinical Site #194
state: Ontario
city: Ottawa
country: Canada
facility: Exelixis Clinical Site #212
state: Ontario
city: Montréal
country: Canada
facility: Exelixis Clinical Site #85
state: Quebec
city: Hefei
country: China
facility: Exelixis Clinical Site #233
state: Anhui
city: Fuzhou
country: China
facility: Exelixis Clinical Site #228
state: Fujian
city: Xiamen
country: China
facility: Exelixis Clinical Site #225
state: Fujian
city: Guangzhou
country: China
facility: Exelixis Clinical Site #242
state: Guangdong
city: Harbin
country: China
facility: Exelixis Clinical Site #227
state: Heilongjiang
city: Zhengzhou
country: China
facility: Exelixis Clinical Site #230
state: Henan
city: Changsha
country: China
facility: Exelixis Clinical Site #231
state: Hunan
city: Changsha
country: China
facility: Exelixis Clinical Site #224
state: Hunan
city: Changsha
country: China
facility: Exelixis Site #241
state: Hunan
city: Nanjing
country: China
facility: Exelixis Clinical Site #185
state: Jiangsu
city: Nanchang
country: China
facility: Exelixis Clinical Site #221
state: Jiangxi
city: Nanchang
country: China
facility: Exelixis Clinical Site #238
state: Jiangxi
city: Jiangyin
country: China
facility: Exelixis Clinical Site #234
state: Jiansu
city: Changchun
country: China
facility: Exelixis Clinical Site #246
state: Jilin
city: Changchun
country: China
facility: Exelixis Clinical Site #229
state: Jilin
city: Shenyang
country: China
facility: Exelixis Clinical Site #236
state: Liaoning
city: Linyi
country: China
facility: Exelixis Clinical Site #226
state: Shandong
city: Chengdu
country: China
facility: Exelixis Clinical Site #235
state: Sichuan
city: Hangzhou
country: China
facility: Exelixis Clinical Site #218
state: Zhejiang
city: Hangzhou
country: China
facility: Exelixis Clinical Site #223
state: Zhejiang
city: Beijing
country: China
facility: Exelixis Site #239
city: Beijing
country: China
facility: Exelixis Clinical Site #237
city: Shanghai
country: China
facility: Exelixis Site #240
city: Shanghai
country: China
facility: Exelixis Clinical Site #232
city: Montería
country: Colombia
facility: Exelixis Clinical Site #130
state: Cordoba
city: Hradec Králové
country: Czechia
facility: Exelixis Clinical Site #18
city: Olomouc
country: Czechia
facility: Exelixis Clinical Site #37
city: Praha 4
country: Czechia
facility: Exelixis Clinical Site #10
city: Praha 5
country: Czechia
facility: Exelixis Clinical Site #38
city: Amiens
country: France
facility: Exelixis Clinical Site #43
city: Besancon
country: France
facility: Exelixis Clinical Site #27
city: Bondy Cedex
country: France
facility: Exelixis Clinical Site #56
city: Caen Cedex 09
country: France
facility: Exelixis Clinical Site #29
city: Clichy
country: France
facility: Exelixis Clinical Site #48
city: Grenoble
country: France
facility: Exelixis Clinical Site #23
city: Lille Cedex
country: France
facility: Exelixis Clinical Site #55
city: Lyon Cedex 4
country: France
facility: Exelixis Clinical Site #16
city: Montbeliard
country: France
facility: Exelixis Clinical Site #31
city: Montpellier
country: France
facility: Exelixis Clinical Site #49
city: Nantes
country: France
facility: Exelixis Clinical Site #47
city: Nice
country: France
facility: Exelixis Clinical Site #51
city: Pessac
country: France
facility: Exelixis Clinical Site #20
city: Vandœuvre-lès-Nancy
country: France
facility: Exelixis Clinical Site #32
city: Batumi
country: Georgia
facility: Exelixis Clinical Site #69
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #66
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #68
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #67
city: Tbilisi
country: Georgia
facility: Exelixis Clinical Site #70
city: Frankfurt
country: Germany
facility: Exelixis Clinical Site #244
state: Hessen
city: Kassel
country: Germany
facility: Exelixis Clinical Site #210
state: Hessen
city: Berlin
country: Germany
facility: Exelixis Clinical Site #214
city: Hamburg
country: Germany
facility: Exelixis Clinical Site #215
city: Hong Kong
country: Hong Kong
facility: Exelixis Clinical Site #146
city: Hong Kong
country: Hong Kong
facility: Exelixis Clinical Site #42
city: Hong Kong
country: Hong Kong
facility: Exelixis Clinical Site #9
city: Budapest
country: Hungary
facility: Exelixis Clinical Site #140
city: Debrecen
country: Hungary
facility: Exelixis Clinical Site #25
city: Szeged
country: Hungary
facility: Exelixis Clinical Site #26
city: Dublin
country: Ireland
facility: Exelixis Clinical Site #170
city: Jerusalem
country: Israel
facility: Exelixis Clinical Site #30
city: Petah Tikva
country: Israel
facility: Exelixis Clinical Site #33
city: Ramat-Gan
country: Israel
facility: Exelixis Clinical Site #40
city: Rehovot
country: Israel
facility: Exelixis Clinical Site #35
city: Tricase
country: Italy
facility: Exelixis Clinical Site #163
state: Lecce
city: Rozzano
country: Italy
facility: Exelixis Clinical Site #53
state: Milano
city: Bologna
country: Italy
facility: Exelixis Clinical Site #158
city: Brescia
country: Italy
facility: Exelixis Clinical Site #152
city: Milan
country: Italy
facility: Exelixis Clinical Site #147
city: Napoli
country: Italy
facility: Exelixis Clinical Site #149
city: Novara
country: Italy
facility: Exelixis Clinical Site #131
city: Roma
country: Italy
facility: Exelixis Clinical Site #167
city: Torino
country: Italy
facility: Exelixis Clinical Site #177
city: Torino
country: Italy
facility: Exelixis Clinical Site #182
city: Udine
country: Italy
facility: Exelixis Clinical Site #243
city: Goyang-si
country: Korea, Republic of
facility: Exelixis Clinical Site #157
state: Gyeonggi-do
city: Suwon
country: Korea, Republic of
facility: Exelixis Clinical Site #127
state: Gyeonggi-do
city: Busan
country: Korea, Republic of
facility: Exelixis Clinical Site #77
city: Busan
country: Korea, Republic of
facility: Exelixis Clinical Site #86
city: Busan
country: Korea, Republic of
facility: Exelixis Clinical Site #114
city: Incheon
country: Korea, Republic of
facility: Exelixis Clinical Site #75
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #104
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #105
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #99
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #79
city: Seoul
country: Korea, Republic of
facility: Exelixis Clinical Site #93
city: Tuxtla Gutiérrez
country: Mexico
facility: Exelixis Clinical Site #141
state: Chiapas
city: León
country: Mexico
facility: Exelixis Clinical Site #135
state: Guanajuato
city: Monterrey
country: Mexico
facility: Exelixis Clinical Site #132
state: Nuevo Leon
city: Ciudad De México
country: Mexico
facility: Exelixis Clinical Site #133
city: Mexico City
country: Mexico
facility: Exelixis Clinical Site #160
city: San Luis Potosí
country: Mexico
facility: Exelixis Clinical Site #134
city: Veracruz
country: Mexico
facility: Exelixis Clinical Site #153
city: Maastricht
country: Netherlands
facility: Exelixis Clinical Site #92
state: Limburg
city: Amsterdam
country: Netherlands
facility: Exelixis Clinical Site #52
state: Noord-Holland
city: Rotterdam
country: Netherlands
facility: Exelixis Clinical Site #84
state: Zuid-Holland
city: Utrecht
country: Netherlands
facility: Exelixis Clinical Site #36
city: Grafton
country: New Zealand
facility: Exelixis Clinical Site #60
state: Auckland
city: Newton
country: New Zealand
facility: Exelixis Clinical Site #62
state: Wellington
city: Cebu City
country: Philippines
facility: Exelixis Clinical Site #118
city: Pasig City
country: Philippines
facility: Exelixis Clinical Site #117
city: Quezon City
country: Philippines
facility: Exelixis Clinical Site #136
city: Warszawa
country: Poland
facility: Exelixis Clinical Site #41
state: Mazowieckie
city: Gdansk
country: Poland
facility: Exelixis Clinical Site #24
state: Pomorskie
city: Mysłowice
country: Poland
facility: Exelixis Clinical Site #15
state: Slaskie
city: Cluj-Napoca
country: Romania
facility: Exelixis Clinical Site #204
state: Cluj
city: Cluj-Napoca
country: Romania
facility: Exelixis Clinical Site #211
state: Cluj
city: Cluj-Napoca
country: Romania
facility: Exelixis Clinical Site #202
state: Cluj
city: Bucuresti
country: Romania
facility: Exelixis Clinical Site #206
city: Iaşi
country: Romania
facility: Exelixis Clinical Site #209
city: Kislino
country: Russian Federation
facility: Exelixis Clinical Site #74
state: Kursk Region
city: Kaluga
country: Russian Federation
facility: Exelixis Clinical Site #81
city: Krasnodar
country: Russian Federation
facility: Exelixis Clinical Site #95
city: Moscow
country: Russian Federation
facility: Exelixis Clinical Site #108
city: Murmansk
country: Russian Federation
facility: Exelixis Clinical Site #101
city: Nizhny Novgorod
country: Russian Federation
facility: Exelixis Clinical Site #80
city: Saint Petersburg
country: Russian Federation
facility: Exelixis Clinical Site #111
city: Saint-Petersburg
country: Russian Federation
facility: Exelixis Clinical Site #90
city: Sochi
country: Russian Federation
facility: Exelixis Clinical Site #73
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #106
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #97
city: Singapore
country: Singapore
facility: Exelixis Clinical Site #116
city: Santander
country: Spain
facility: Exelixis Clinical Site #28
state: Cantabria
city: Majadahonda
country: Spain
facility: Exelixis Clinical Site #21
state: Madrid
city: Majadahonda
country: Spain
facility: Exelixis Clinical Site #22
state: Madrid
city: Pamplona
country: Spain
facility: Exelixis Clinical Site #59
state: Navarra
city: Barcelona
country: Spain
facility: Exelixis Clinical Site #103
city: Madrid
country: Spain
facility: Exelixis Clinical Site #164
city: Madrid
country: Spain
facility: Exelixis Clinical Site #63
city: Valencia
country: Spain
facility: Exelixis Clinical Site #168
city: Zaragoza
country: Spain
facility: Exelixis Clinical Site #45
city: Basel
country: Switzerland
facility: Exelixis Clinical Site #115
city: Bern
country: Switzerland
facility: Exelixis Clinical Site #172
city: Saint Gallen
country: Switzerland
facility: Exelixis Clinical Site #110
city: Zurich
country: Switzerland
facility: Exelixis Clinical Site #61
city: Changhua
country: Taiwan
facility: Exelixis Clinical Site #119
city: Kaohsiung
country: Taiwan
facility: Exelixis Clinical Site #162
city: Taichung
country: Taiwan
facility: Exelixis Clinical Site #161
city: Tainan City
country: Taiwan
facility: Exelixis Clinical Site #197
city: Tainan
country: Taiwan
facility: Exelixis Clinical Site #145
city: Taipei
country: Taiwan
facility: Exelixis Clinical Site #82
city: Taipei
country: Taiwan
facility: Exelixis Clinical Site #128
city: Taipei
country: Taiwan
facility: Exelixisi Clinical Site #100
city: Taoyuan
country: Taiwan
facility: Exelixis Clinical Site #94
city: Pathum Wan
country: Thailand
facility: Exelixis Clinical Site #96
state: Bangkok
city: Hat Yai
country: Thailand
facility: Exelixis Clinical Site #139
state: Songkla
city: Chiang Mai
country: Thailand
facility: Exelixis Clinical Site #143
city: Khon Kaen
country: Thailand
facility: Exelixis Clinical Site #183
city: Istanbul
country: Turkey
facility: Exelixis Clinical Site #189
state: Instanbul
city: Ankara
country: Turkey
facility: Exelixis Clinical Site #193
city: Ankara
country: Turkey
facility: Exelixis Clinical Site #178
city: Edirne
country: Turkey
facility: Exelixis Clinical Site #173
city: Istanbul
country: Turkey
facility: Exelixis Clinical Site #179
city: Malatya
country: Turkey
facility: Exelixis Clinical Site #180
city: Chernivtsi
country: Ukraine
facility: Exelixis Clinical Site #125
city: Dnipro
country: Ukraine
facility: Exelixis Clinical Site #122
city: Kharkiv
country: Ukraine
facility: Exelixis Clinical Site #123
city: Odesa
country: Ukraine
facility: Exelixis Clinical Site #124
city: Uzhhorod
country: Ukraine
facility: Exelixis Clinical Site #138
city: Bristol
country: United Kingdom
facility: Exelixis Clinical Site #83
state: England
city: Cambridge
country: United Kingdom
facility: Exelixis Clinical Site #87
state: England
city: London
country: United Kingdom
facility: Exelixis Clinical Site #151
state: England
city: London
country: United Kingdom
facility: Exelixis Clinical Site #129
state: England
city: Manchester
country: United Kingdom
facility: Exelixis Clinical Site #192
state: England
city: Belfast
country: United Kingdom
facility: Exelixis Clinical Site #196
state: Northern Ireland
Study officials:
References:
citation: Kelley RK, Rimassa L, Cheng AL, Kaseb A, Qin S, Zhu AX, Chan SL, Melkadze T, Sukeepaisarnjaroen W, Breder V, Verset G, Gane E, Borbath I, Rangel JDG, Ryoo BY, Makharadze T, Merle P, Benzaghou F, Banerjee K, Hazra S, Fawcett J, Yau T. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2022 Aug;23(8):995-1008. doi: 10.1016/S1470-2045(22)00326-6. Epub 2022 Jul 4.
citation: Kelley RK, W Oliver J, Hazra S, Benzaghou F, Yau T, Cheng AL, Rimassa L. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design. Future Oncol. 2020 Jul;16(21):1525-1536. doi: 10.2217/fon-2020-0283. Epub 2020 Jun 3.